pipeline

Unleashing Our innovative Targeted Therapeutics Redefines Cancer Treatment

Pipeline

Our pipeline is dedicated to pioneering innovative cancer therapeutics. We focus on developing small molecule BAK activator, bispecific antibodies, and BAK activator-linked bispecific antibody drug conjugates (BADCs).

Program

Indication

Discovery

Preclinical

Phase I

Phase II

Phase III

NDA

Notes

7PB-100

(BAK Activator)

7PB-100

Non-Small Cell Lung Cancer/Small Cell Lung Cancer

Licensed From

7PB-100

+ Venetoclax

7PB-100

+ Venetoclax

Non-Small Cell Lung Cancer/Small Cell Lung Cancer

Licensed From

7PB-200

(Bispecific antibody for Undisclosed TAAs)

7PB-200

Solid Tumors

CombYSelect Licensed from

In House Discovery 

7PB-300

(Bispecific Antibody-drug Conjugate for Undisclosed TAAs)

7PB-300

Solid Tumors

CombYSelect Licensed from

In House Discovery 

Program

7PB-100

(BAK Activator)

Indication

Non-Small Cell Lung Cancer/Small Cell Lung Cancer

Discovery

Preclinical

Phase I

Phase II

Phase III

NDA

Notes

Licensed From

Program

7PB-100

+ Venetoclax

Indication

Non-Small Cell Lung Cancer/Small Cell Lung Cancer

Discovery

Preclinical

Phase I

Phase II

Phase III

NDA

Notes

Licensed From

Program

7PB-200

(Bispecific antibody for Undisclosed TAAs)

Indication

Solid Tumors

Discovery

Preclinical

Phase I

Phase II

Phase III

NDA

Notes

CombYSelect Licensed from

In House Discovery 

Program

7PB-300

(Bispecific Antibody-drug Conjugate for Undisclosed TAAs)

Indication

Solid Tumors

Discovery

Preclinical

Phase I

Phase II

Phase III

NDA

Notes

CombYSelect Licensed from

In House Discovery 

Have questions or want to know more about our ground breaking targeted cancer therapeutics? Feel free to reach out to our dedicated team.

Contact us

© 2024 7 PRIMUS BIOSCIENCES

7PB-100

7PB-100 is the first-in-class small molecule BAK activator with potent anti-proliferative efficacy and minimal toxicity to normal tissues. By selectively binding to the BH3 region of the BAK molecule, it induces oligomerization of the BAK molecule, cytochrome c release, and ultimately apoptotic cell death. It also shows a potent synergistic effect with the Bcl-2 inhibitor venetoclax against lung cancer xenografts, offering a promising treatment option for lung cancer and other cancers with high BAK expression.

7PB-200

7PB-200 is an IgG1-like bispecific antibody targeting undisclosed tumor-associated antigens to block tumorigenesis. It is made up of different IgG1 heterodimers paired through the CombYSelect platform for a long half-life, stability, and enhanced functionality. In vitro, it specifically binds to undisclosed TAAs (Tumor-Associated Antigens) and effectively suppresses tumor growth in in vivo models expressing TAAs. Its ability to target dual TAAs helps prevent tumor antigen escape, ensuring sustained effectiveness and improved therapeutic impact on cancer cells.

7PB-300

7PB-300 is a bispecific antibody-drug conjugate that links a bispecific antibody to undisclosed Tumor-Associated Antigens (TAAs) and the BAK activator, 7PB-100, as a payload. This approach reduces toxicity from unintended payload release by specifically targeting cancer cells with high BAK expression, while causing less harm to normal cells with little or no BAK expression. Targeting dual TAAs helps overcome tumor antigen escape, ensuring sustained efficacy. Specifically delivering 7PB-100 to cancer cells is expected to significantly increase the therapeutic index on cancer cells, showing reduced side effects from off-target and off-tumor related toxicities compared to traditional cytotoxic ADCs.